ClinicalTrials.gg
Enrolling by invitationNCT07486076HBM-osteo-eduUpdated Aug 20, 2026

OSTEOPOROSIS EDUCATION AND ITS IMPACT ON OSTEOPOROSIS HEALTH BELIEFS AND AWARENESS IN WOMEN AT RISK OF OSTEOPOROSIS

An interventional study of Osteoporosis Education Based on the Health Belief Model in Health Belief Model-Based Osteoporosis Education Programme, sponsored by Bartın Unıversity. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 45 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Bartın Unıversity · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Osteoporosis with a site in Turkey — 14 open to participants now, 17 under way, none of them phase 3. Osteoporosis · Turkey.

Planned enrollment
13th of 31
74 · median 60
Started
2026
with 9 others
No phase
26 of 67
3 open now
Primary completion
2027-01
later than 15 of 16 live
Registered
59th of 67
by date

Among the 67 studies in Osteoporosis with a site in Turkey, this one is the 13th largest by planned enrollment of the 31 interventional ones that give a count, is one of 10 that started in 2026, is one of 26 with no phase, reaches primary completion later than 15 of the 16 other live ones, and was the 59th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

14 of the 67 studies in Osteoporosis with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 80 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Osteoporosis with a site in Turkey, or all of them as a file.
02

Study summary

Osteoporosis is a significant public health problem characterized by low bone mass and deterioration in the microarchitecture of bone tissue, leading to an increased risk of fractures. Risk factors such as advanced age, female gender, inadequate calcium and vitamin D intake, physical inactivity, smoking, and alcohol use play a critical role in its development. As in many countries, the prevalence of osteoporosis is increasing in Turkey, accelerated by an aging population and lifestyle changes. However, it is reported that the level of awareness and knowledge about osteoporosis in the community is often insufficient.

This study is a randomized controlled experimental trial with a two-group pretest-posttest design, conducted between February 1 and June 1, 2026, among women aged 45 and older who have not been diagnosed with osteoporosis but carry at least one osteoporosis risk factor, attending the Physical Therapy and Rehabilitation outpatient clinic at Bartın State Hospital. From the study population, participants who meet the inclusion criteria and volunteer will be randomly assigned to intervention and control groups. The sample size is determined as 74, calculated with a 95% confidence level and a 5% margin of error. While the intervention group receives a structured education program based on the Health Belief Model, the control group will receive no education.

The dependent variables of the study are osteoporosis awareness and health beliefs. These variables will be measured before and after the intervention using the Osteoporosis Awareness Scale and the Osteoporosis Health Belief Scale, which includes subdimensions of perceived susceptibility, seriousness, benefits, and barriers. The effectiveness of the education program will be evaluated through inter-group and intra-group comparisons.

Read the detailed description

Osteoporosis is the most common musculoskeletal disorder worldwide, characterized by low bone mass and deterioration of the microarchitecture of bone tissue. This condition, which can lead to functional loss and increased mortality, is a significant public health problem that is both preventable and treatable. Approximately 90% of peak bone mass is achieved by age 18 in women and age 20 in men; low peak bone mass is considered a primary determinant of osteoporotic fracture risk in later life. Studies indicate that the prevalence of osteoporosis among older individuals is significant, emphasizing that the foundations of the disease are laid during adolescence.

The most serious complications of osteoporosis are fractures, which are associated with high costs, loss of independence, and mortality. These fractures most commonly occur in the spine, wrist, and hip. In postmenopausal women, wrist and spinal fractures increase after age 50, while hip fractures typically appear at later ages. Epidemiological data show varying rates of osteoporosis prevalence globally, which is notably higher in postmenopausal women. In this context, early identification of osteoporosis risk in women is critical.

Osteoporosis is classified into primary and secondary categories. Primary osteoporosis results from decreased bone mineralization due to aging or menopause, appearing more frequently 10-15 years after menopause in women and between ages 75-80 in men. Primary osteoporosis is further divided into Type 1 (postmenopausal) and Type 2 (senile). Type 1 is related to estrogen deficiency, whereas Type 2 is a natural consequence of aging, involving both cortical and trabecular bone loss. Vitamin D deficiency, decreased calcium absorption, and reduced osteoblast activity accelerate the development of Type 2. Secondary osteoporosis is associated with bone loss resulting from specific diseases or medication use.

In determining osteoporosis risk, identifying women who have not yet been diagnosed but carry specific risk factors is of vital importance. Literature reports that osteoporosis is more prevalent in women than men due to decreasing bone mineral density and increasing fragility. Primary causes include advancing age, postmenopausal estrogen decline, low body mass index, smoking, and a family history of osteoporosis. Risk factors also include modifiable and non-modifiable elements such as low calcium and vitamin D intake, inadequate physical activity, and long-term corticosteroid use. Women at risk can be defined as those who, despite lacking a formal diagnosis, possess at least one of these biological, hormonal, or lifestyle risk factors.

In addition to these factors, a lack of knowledge, misconceptions, and low awareness among women adversely affect disease prevention. Knowledge levels are often lower in rural areas, where the role of primary care physicians in information dissemination is critical. Insufficient health beliefs and knowledge levels reduce participation in screening programs and hinder early preventive measures.

According to guidelines published by global health organizations, bone density measurement is recommended for individuals at risk. This includes all women aged 65 and older, all men aged 70 and older, and younger adults with fracture risks. Furthermore, for individuals aged 50 and over, DXA screening is advised in the presence of risk factors such as a history of minimal trauma fractures, glucocorticoid therapy, postmenopausal status, low body weight (\<57 kg), family history of hip fracture, and smoking.

Organizations such as the American Association of Clinical Endocrinologists (AACE) and the National Osteoporosis Foundation (NOF) similarly recommend the routine use of DXA as a screening tool for specific age groups and clinical findings. Early diagnosis through bone density measurement, particularly in postmenopausal women and women under 65 with risk factors, is considered an effective strategy for fracture prevention. Assessing risk allows for the detection of osteoporosis during the asymptomatic stage, enabling timely preventive and therapeutic interventions. This prevents osteoporotic fractures and related complications. Individuals with a history of low-trauma fractures or those at risk for age-related bone loss should be included in regular health check-ups and monitored with bone density tests. Periodic repetition of DXA measurements is also important for monitoring treatment efficacy and assessing the progression of bone loss.

The Health Belief Model (HBM) provides an important theoretical framework for understanding the factors that shape health-related behaviors. This model focuses on the beliefs and perceptions that influence the adoption of health behaviors. The primary goal of the HBM is to explain the beliefs necessary for individuals to engage in health-promoting behaviors. In addition to individual characteristics, the model emphasizes that environmental factors play a significant role. Education and interventions can help individuals modify these perceptions, resulting in positive changes in health behaviors.

International literature features various studies using the Health Belief Model as an effective framework for explaining and guiding osteoporosis-related knowledge, attitudes, and preventive behaviors. Research indicates that following a structured education program, participants show a significant increase in awareness regarding preventive behaviors-such as exercise, vitamin D, and calcium intake-alongside positive shifts in health belief components, including perceived susceptibility, seriousness, benefits, barriers, and self-efficacy.

03

Conditions studied

  • Health Belief Model-Based Osteoporosis Education Programme

Browse trials for

Keywords

  • Health Belief Model-Based Education
  • Osteoporosis Awareness
  • Health Beliefs in Woman
  • Osteoporosis risk
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria: Individuals meeting the following criteria will be included in the study:

    • Being a woman aged 45 and over
    • Not having been diagnosed with osteoporosis
    • Having at least one of the risk factors for osteoporosis development as stated in the literature (being in menopause, family history of osteoporosis, low level of physical activity, insufficient calcium/vitamin D intake, low , etc.)
    • Having applied to the Physical Therapy and Rehabilitation Outpatient Clinic of Bartın State Hospital
    • Volunteering to participate in the study and signing the form
    • Having the cognitive and physical capacity to participate in the training sessions

Exclusion Criteria:Exclusion Criteria: Individuals with the following characteristics will be excluded from the study:

  • Having a previous diagnosis of osteoporosis
  • Having a serious endocrine or rheumatological disease affecting bone metabolism
  • Having a history of long-term (≥ 3 months) systemic use
  • Having participated in a structured education program related to osteoporosis within the last 6 months
  • Having hearing, vision, or cognitive impairment that would prevent participation in the education program
  • Wishing to withdraw from the study or being unable to complete the follow-up process-
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
74 participants (estimated)

Study arms

  • No intervention
    The Control Group: The group not receiving HBM based osteoporosis training

    Participants in the control group will receive only routine information without any additional educational intervention.Questionnaires will be administered before and four weeks after the intervention.

  • Experimental
    Experimental: The group receiving HBM based osteoporosis training

    Participants in the intervention group will receive an osteoporosis education program developed by the researchers based on the Health Belief Model. The educational content includes the definition of osteoporosis, risk factors, prevention methods, and healthy lifestyle behaviors, structured according to perceived susceptibility, severity, benefits, and barriers.

    Behavioral: Osteoporosis Education Based on the Health Belief Model

Interventions

  • BehavioralOsteoporosis Education Based on the Health Belief Model

    Intervention Description This study evaluates a hybrid educational program based on the Health Belief Model (HBM), focusing on perceived susceptibility, severity, benefits, and barriers. 1. Baseline Assessment: Participants in both groups complete questionnaires on osteoporosis awareness and health beliefs. 2. Educational Intervention (Intervention Group): Initial Session: A 45-60 minute structured face-to-face training covering osteoporosis definition, risk factors, and prevention through nutrition and exercise. Digital Support: A 4-week follow-up via WhatsApp, involving twice-weekly distribution of educational videos, digital brochures, and podcasts to reinforce healthy behaviors. 3. Final Assessment: Four weeks post-intervention, both groups repeat the baseline questionnaires. Control Group: Receives routine clinical information only. To prevent contamination, all educational materials are shared with this group only after the final data collection is completed.

06

What researchers measure

Primary outcomes

  1. Change in Osteoporosis Awareness Scale (OAS) score.

    The Osteoporosis Awareness Scale (OAS) consists of 27 items with a total score ranging from a minimum of 27 to a maximum of 108, where higher scores indicate a greater level of osteoporosis awareness, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention.

  2. Change in Osteoporosis Health Belief Scale Score

    The Total Osteoporosis Health Belief Scale (OHBS) score is the sum of 42 items ranging from 42 to 210, where higher scores indicate more positive health beliefs and stronger perceptions toward osteoporosis prevention, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention..

  3. Change in Osteoporosis Health Belief Scale - Perceived Seriousness Sub-dimension Score.

    The Perceived Susceptibility sub-dimension (6 items) assesses the individual's perceived risk of developing osteoporosis with scores ranging from 6 to 30, where higher scores indicate a stronger perception of personal risk, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention.

  4. Change in Osteoporosis Health Belief Scale - Benefits of Exercise Sub-dimension Score.

    The Barriers to Exercise sub-dimension (6 items) identifies perceived obstacles to regular physical activity with scores ranging from 6 to 30, where lower scores indicate fewer perceived barriers, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention.

  5. Change in Osteoporosis Health Belief Scale - Benefits of Calcium Intake Sub-dimension Score.

    The Barriers to Calcium Intake sub-dimension (6 items) evaluates perceived difficulties in maintaining adequate calcium consumption with scores ranging from 6 to 30, where lower scores indicate fewer perceived obstacles, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention.

  6. Change in Osteoporosis Health Belief Scale - Barriers to Exercise Sub-dimension Score.

    This sub-dimension consists of 6 items (Items 25-30) identifying perceived obstacles to engaging in regular exercise. The minimum score is 6 and the maximum score is 30. Higher scores indicate greater perceived barriers to exercise. (Note: In this context, a decrease in this score post-intervention would typically be the desired clinical goal.)

    Time frame: Baseline and 4 weeks post-intervention.

  7. Change in Osteoporosis Health Belief Scale - Barriers to Calcium Intake Sub-dimension Score.

    This sub-dimension consists of 6 items (Items 31-36) identifying perceived difficulties in maintaining adequate calcium intake. The minimum score is 6 and the maximum score is 30. Higher scores indicate greater perceived barriers to calcium consumption.

    Time frame: Baseline and 4 weeks post-intervention.

  8. Change in Osteoporosis Health Belief Scale - Health Motivation Sub-dimension Score.

    The Health Motivation sub-dimension (6 items) assesses the individual's general drive to engage in health-protective behaviors with scores ranging from 6 to 30, where higher scores indicate greater motivation to maintain bone health.

    Time frame: Baseline and 4 weeks post-intervention.

  9. Changes in Perceived Susceptibility Sub-dimension Score

    The Perceived Susceptibility sub-dimension (6 items) assesses the individual's perceived risk of developing osteoporosis with scores ranging from 6 to 30, where higher scores indicate a stronger perception of personal risk, representing a better outcome.

    Time frame: Baseline and 4 weeks post-intervention.

07

Study locations

1 site
08

References and documents

Publications

  • Ocak Aktürk, S., Meseri, R., & Özentürk, M. G. (2021). The psychometric property evaluation of the Turkish version of the Osteoporosis Awareness Scale. Turkish Journal of Osteoporosis, 27(3), 151-158.https://doi.org/10.4274/tod.galenos.2021.22590
  • Kılıç, D., & Erci, B. (2004). Osteoporoz sağlık ölçeği, osteoporoz öz-etkililik-yeterlik ölçeği ve osteoporoz bilgi testinin geçerlilik ve güvenirliği. Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi, 7(2), 89-102
  • Huo R, Wei C, Huang X, Yang Y, Huo X, Meng D, Huang R, Huang Y, Zhu X, Yang Y, Lin J. Mortality associated with osteoporosis and pathological fractures in the United States (1999-2020): a multiple-cause-of-death study. J Orthop Surg Res. 2024 Sep 16;19(1):568. doi: 10.1186/s13018-024-05068-1. PubMed 39285484 ↗
  • Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem. 2017 Feb;63(2):464-474. doi: 10.1373/clinchem.2016.259085. Epub 2016 Dec 9. PubMed 27940448 ↗
  • Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69. PubMed 27681935 ↗
  • Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. PubMed 25182228 ↗
  • Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020 May;26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. PubMed 32427503 ↗
  • Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021 Jun 2;16(1):82. doi: 10.1007/s11657-020-00871-9. PubMed 34080059 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 8 months is below that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 20, 2026
StartActual
Apr 25, 2026
Primary completionEst.
Jan 20, 2027
CompletionEst.
Feb 25, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486076
Lead sponsor
Bartın Unıversity
Responsible party
Ayfer Bayındır Çevik (Prof.Dr.Ayfer Bayındır Çevik, Bartın Unıversity) — Principal investigator
First posted
Mar 20, 2026
Start date
Apr 25, 2026
Primary completion
Jan 20, 2027 (estimated)
Completion
Feb 25, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Taqwa İbrahim Hasan Hasan Hasan Hasan, bachelor
principal investigator · Bartın Unıversity
Ayfer Bayındır Çevik Çevik Çevik, Professor
principal investigator · Bartın Unıversity

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion